CABANA will affect my clinical decision making in atrial fibrillation ablation - PRO
Speaker Riccardo Cappato
Event : EHRA 2019
- Topic : arrhythmias and device therapy
- Sub-topic : Atrial Fibrillation - Treatment
- Session type : Debate Session
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.